INO Earnings

INO reported its earnings on 2026-03-12, showcasing a revenue of against an estimate of 80.00K, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.37 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following INO's earnings announcement on 2026-03-12, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, INO's stock price tends to shift by an average of 7.4% in the 10 days leading up to earnings and -2.5% in the 10 days following, providing insight into potential market.

For , analysts estimate INO's annual revenue to reach , while the EPS is projected at -0.37. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between INO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, INO's stock price typically moves by 7.4% in the 10 days before its earnings and -2.5% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.37 and revenue of .

The earnings call indicates a balanced outlook. While there are positive developments such as the FDA acceptance and market potential for INO-3107, the absence of immediate revenue impact and the need for confirmatory trials suggest caution. The company's financial health appears stable until 2026, but potential capital raises could be a concern. The Q&A session did not reveal significant negative sentiments from analysts, but management's lack of clarity on certain aspects, like the M&A pipeline, tempers optimism. Overall, the sentiment is neutral with no strong catalysts for immediate stock price movement.